Portal de Periódicos da CAPES

Hirsutismo, flutamida y toxicidad hepática

2001; Elsevier BV; Volume: 24; Issue: 4 Linguagem: Inglês

10.1016/s0210-5705(01)70153-7

1578-9519

M.L. Ruiz-Rebollo, R. Atienza-Sánchez, E. López-GarcíL,

Assisted Reproductive Technology and Twin Pregnancy

To evaluate the long-term safety and tolerability of flutamide therapy for hirsutism.Prospective observational study.Gynecology department in a teaching hospital.Hyperandrogenic women presenting for hirsutism treatment were followed between January 2000 and January 2007.Women received flutamide 250 mg/day alone (n = 27) or combined with a fixed dose of an oral contraceptive containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (n = 56).Adverse events, safety, tolerability and efficacy were assessed every 6 months during the follow-up. Liver and lipid profiles were also recorded.Patients under flutamide therapy showed, compared with basal values, a significant progressive decrease in hirsutism scores after 6 months of treatment with a maximum effect at 12 months that was maintained during the 84 months of follow-up. A total of 40.96% women presented one or more adverse effects during the follow-up; 33.73% showed at least one adverse effect possibly related with the study drug, and 24.09% withdrew from the study because of adverse effects. During the follow-up, as many as 59% of patients abandoned the study.Flutamide is very effective for hirsutism treatment; however, adverse effects are very frequent and associated with low long-term compliance.